Drug Intelligence Bulletin

Drug Intelligence Bulletin

Share this post

Drug Intelligence Bulletin
Drug Intelligence Bulletin
A New Synthetic Opioid Is on the Black Market: 2-Methyl AP-237
Copy link
Facebook
Email
Notes
More

A New Synthetic Opioid Is on the Black Market: 2-Methyl AP-237

Keith Graves's avatar
Keith Graves
Jun 21, 2019
1

Share this post

Drug Intelligence Bulletin
Drug Intelligence Bulletin
A New Synthetic Opioid Is on the Black Market: 2-Methyl AP-237
Copy link
Facebook
Email
Notes
More
Share

On average, one new synthetic drug comes to the black market. These drugs are often referred to as Novel Psychoactive Substances (NPS) in the medical community, Research Chemicals (RC) in the drug using crowd, or "Legal Highs" by some lay people.

2-Methyl AP-237

No matter what you call it, it is concerning that so many of these new drugs are coming to the market so quickly. This week's newest drug coming to the black market is a drug called 2-Methyl AP-237. 2-Methyl AP-237 is classified as a synthetic opioid. 2-Methyl AP-237 is structurally distinct from fentanyl, its analogues, and other synthetic opioids previously reported.

2-Methyl AP-237 is an analogue of bucinnazine (AP-237), an opioid used therapeutically; although bucinnazine is not prescribed within the United States. Bucinnazine is used in China to treat cancer. It is one of the most potent compounds among a series of analgesic acyl piperazines compounds first synthesized and reported in Japan in the 1970s. Bucinnazine has analgesic potency comparable to that of morphine but with a relatively higher therapeutic index.

The chemical structure of 2-Methyl AP-237

Legal Status of 2-Methyl AP-237

Based on its recent emergence and potential for abuse within the United States and worldwide, 2-methyl AP-237 has been categorized as a Novel Psychoactive Substance (NPS). 2-Methyl AP-237 and bucinnazine are not scheduled substances in the United States. What does this mean? It isn't illegal and makes it attractive for those wishing to abuse opioids, but don't want to get arrested. It also means that most workplaces won't test for it. That means your safety sensitive employees can get high on it and still test clean in a reasonable suspicion testing scenario.

Like all other opioids, 2-Methyl AP-237 is highly addictive. Tolerance will develop quickly after chronic administration. It will also relieve withdrawal symptoms if the person is addicted to another opioid.

A simple google search will show you numerous places that it can be purchased online. As with most new synthetic drugs, this drug is sold from China.


Subscribe to Drug Intelligence Bulletin

By Keith Graves · Hundreds of paid subscribers
The latest training and intelligence on new & emerging drugs, current drug trends, drug cartels and drug policy. Subscribe now.
Erica Bowlin's avatar
1 Like
1

Share this post

Drug Intelligence Bulletin
Drug Intelligence Bulletin
A New Synthetic Opioid Is on the Black Market: 2-Methyl AP-237
Copy link
Facebook
Email
Notes
More
Share

Discussion about this post

User's avatar
New Fentanyl Analog Entered the Drug Supply: ortho-Methylfentanyl
Drug Intelligence Bulletin is a reader-supported publication.
Jan 9, 2024 • 
Keith Graves
62

Share this post

Drug Intelligence Bulletin
Drug Intelligence Bulletin
New Fentanyl Analog Entered the Drug Supply: ortho-Methylfentanyl
Copy link
Facebook
Email
Notes
More
Narco News Weekly 01/08/2024
In this edition:
Jan 8, 2024 • 
Keith Graves
55

Share this post

Drug Intelligence Bulletin
Drug Intelligence Bulletin
Narco News Weekly 01/08/2024
Copy link
Facebook
Email
Notes
More
Narco News 01/15/24
In this edition
Jan 15, 2024 • 
Keith Graves
53

Share this post

Drug Intelligence Bulletin
Drug Intelligence Bulletin
Narco News 01/15/24
Copy link
Facebook
Email
Notes
More

Ready for more?

© 2025 Graves and Associates INC
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share

Copy link
Facebook
Email
Notes
More

Create your profile

User's avatar

Only paid subscribers can comment on this post

Already a paid subscriber? Sign in

Check your email

For your security, we need to re-authenticate you.

Click the link we sent to , or click here to sign in.